{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:43:48Z","timestamp":1787067828371,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00535-024-02190-z","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T01:14:13Z","timestamp":1733361253000},"page":"285-293","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Estimating cancer risk in immune-mediated inflammatory diseases exposed to varying doses of tumour necrosis factor inhibitors"],"prefix":"10.1007","volume":"60","author":[{"given":"Shinji","family":"Okabayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Itaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9034-4370","authenticated-orcid":false,"given":"Hajime","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Isshiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"2190_CR1","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Prim. 2018;4:18001.","journal-title":"Nat Rev Dis Prim"},{"key":"2190_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","volume":"402","author":"C Le Berre","year":"2023","unstructured":"Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402:571\u201384.","journal-title":"Lancet"},{"key":"2190_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2020.18936","volume":"325","author":"K Cushing","year":"2021","unstructured":"Cushing K, Higgins PDR. Management of Crohn disease: a review. JAMA. 2021;325:69\u201380.","journal-title":"JAMA"},{"key":"2190_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945\u201360.","journal-title":"JAMA"},{"key":"2190_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3892\/br.2012.42","volume":"1","author":"X Ma","year":"2013","unstructured":"Ma X, Xu S. TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep. 2013;1:177\u201384.","journal-title":"Biomed Rep"},{"key":"2190_CR6","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1\u2013106.","journal-title":"Gut"},{"key":"2190_CR7","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029\u201372.","journal-title":"J Am Acad Dermatol"},{"key":"2190_CR8","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275\u201385.","journal-title":"JAMA"},{"key":"2190_CR9","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jaad.2017.07.013","volume":"77","author":"D Fiorentino","year":"2017","unstructured":"Fiorentino D, Ho V, Lebwohl MG, et al. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol. 2017;77:845-854.e5.","journal-title":"J Am Acad Dermatol"},{"key":"2190_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S2468-1253(19)30362-0","volume":"5","author":"AK Waljee","year":"2020","unstructured":"Waljee AK, Higgins PDR, Jensen CB, et al. Anti-tumour necrosis factor-\u03b1 therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. Lancet Gastroenterol Hepatol. 2020;5:276\u201384.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2190_CR11","doi-asserted-by":"crossref","unstructured":"Wadstr\u00f6m H, Frisell T, Askling J, Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden. JAMA Intern Med. 2017;177:1605\u201312.","DOI":"10.1001\/jamainternmed.2017.4332"},{"key":"2190_CR12","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","volume":"318","author":"M Lemaitre","year":"2017","unstructured":"Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679\u201386.","journal-title":"JAMA"},{"key":"2190_CR13","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1001\/jama.2014.5613","volume":"311","author":"N Nyboe Andersen","year":"2014","unstructured":"Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311:2406\u201313.","journal-title":"JAMA"},{"key":"2190_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2190_CR15","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023\u201375.","journal-title":"Lancet"},{"key":"2190_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1265\/ehpm.22-00106","volume":"28","author":"S Yoshida","year":"2023","unstructured":"Yoshida S, Tanaka S, Okada M, et al. Develeopment and validation of ischemic heart disease and stroke prognostic models using large-scale real-world data from Japan. Environ Health Prev Med. 2023;28:16.","journal-title":"Environ Health Prev Med"},{"key":"2190_CR17","doi-asserted-by":"publisher","first-page":"430","DOI":"10.5414\/CP204372","volume":"61","author":"R Inose","year":"2023","unstructured":"Inose R, Nakamura A, Omi R, et al. Risks of malignant lymphoma in rheumatoid arthritis patients receiving methotrexate-alone and in combination therapy compared with the general population: a study based on a Japanese medical claims database. Int J Clin Pharmacol Ther. 2023;61:430\u20136.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2190_CR18","doi-asserted-by":"crossref","unstructured":"Raaschou P, Simard JF, Asker Hagelberg C, et al; ARTIS Study Group. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. BMJ 2016:352:i262.","DOI":"10.1136\/bmj.i262"},{"key":"2190_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"issue":"6","key":"2190_CR20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","volume":"133","author":"PC Austin","year":"2016","unstructured":"Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133(6):601\u20139.","journal-title":"Circulation"},{"key":"2190_CR21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326.","journal-title":"N Engl J Med"},{"key":"2190_CR22","unstructured":"Cancer Statistics in Japan 2022. https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/pdf\/cancer_statistics_2022_fig_E.pdf. Accessed 23 May 2024"},{"key":"2190_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2022-001037","volume":"10","author":"J Yu","year":"2023","unstructured":"Yu J, Refsum E, Wieszczy P, et al. Risk of malignant lymphomas in patients with inflammatory bowel disease: a population-based cohort study. BMJ Open Gastroenterol. 2023;10: e001037.","journal-title":"BMJ Open Gastroenterol"},{"key":"2190_CR24","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1016\/j.cgh.2023.04.001","volume":"21","author":"O Ol\u00e9n","year":"2023","unstructured":"Ol\u00e9n O, Smedby KE, Erichsen R, et al. Increasing risk of lymphoma over time in Crohn\u2019s disease but not in ulcerative colitis: a scandinavian cohort study. Clin Gastroenterol Hepatol. 2023;21:3132\u201342.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2190_CR25","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.3390\/cancers15153824","volume":"15","author":"A Massano","year":"2023","unstructured":"Massano A, Bertin L, Zingone F, et al. Extraintestinal cancers in inflammatory bowel disease: a literature review. Cancers (Basel). 2023;15:3824.","journal-title":"Cancers (Basel)"},{"key":"2190_CR26","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","volume":"156","author":"S Vaengebjerg","year":"2020","unstructured":"Vaengebjerg S, Skov L, Egeberg A, et al. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol. 2020;156:421\u20139.","journal-title":"JAMA Dermatol"},{"key":"2190_CR27","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/art.40017","volume":"69","author":"K Hellgren","year":"2017","unstructured":"Hellgren K, Baecklund E, Backlin C, et al. Rheumatoid arthritis and risk of malignant lymphoma: is the risk still increased? Arthritis Rheumatol. 2017;69:700\u20138.","journal-title":"Arthritis Rheumatol"},{"key":"2190_CR28","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/apt.16050","volume":"52","author":"A Chupin","year":"2020","unstructured":"Chupin A, Perduca V, Meyer A, et al. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and\/or thiopurines in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52:1289\u201397.","journal-title":"Aliment Pharmacol Ther"},{"key":"2190_CR29","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1111\/bjd.16245","volume":"178","author":"MR Kamstrup","year":"2018","unstructured":"Kamstrup MR, Skov L, Zachariae C, et al. Psoriasis and risk of malignant lymphoma: a population-based cohort study. Br J Dermatol. 2018;178:1435\u20136.","journal-title":"Br J Dermatol"},{"key":"2190_CR30","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1002\/art.20311","volume":"50","author":"F Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheumatol. 2004;50:1740\u201351.","journal-title":"Arthritis Rheumatol"},{"key":"2190_CR31","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/art.21675","volume":"54","author":"E Baecklund","year":"2006","unstructured":"Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheumatol. 2006;54:692\u2013701.","journal-title":"Arthritis Rheumatol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02190-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-024-02190-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-024-02190-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T06:16:16Z","timestamp":1741068976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-024-02190-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2190"],"URL":"https:\/\/doi.org\/10.1007\/s00535-024-02190-z","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HY reports lecture fees from Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma, Kowa Co. Ltd, AstraZeneca K.K., Kyorin Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co. Ltd. Under contracts with Kyoto University, fees for consultation to HY were paid to Kyoto University from Takeda Pharmaceutical Co. Ltd. and Magmitt Pharmaceutical Co. Ltd. MI is an employee of IQVIA Solutions Japan G.K. YY has received joint research funds from IQVIA Solutions Japan G.K.\u00a0The other authors have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}